Inhibitors of prototypic galectin dimerization and uses thereof
US10519239B2 · kind B2 · utility
1Cited by
0References
19Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | May 25, 2016 |
| Grant date | Dec 31, 2019 |
| Priority date | — |
| Expiry date | May 25, 2036 |
Classification
- Technology area (CPC G)Physics
- CPC primaryG01N2800/7028
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
Agents that inhibit the dimerization of a prototypic galectin such as galectin-7 are described. These agents, for example antibodies and peptides, bind to a domain corresponding to residues 13-25, 86-108 and/or 129-135 of human galectin-7. The use of such agents to inhibit a biological, physiological and/or pathological process that involves prototypic galectin dimerization, for example for the inhibition of galectin-7-mediated apoptosis and the treatment of galectin-7-expressing cancers, is also described.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.